Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

 
• By Michael Cipriano
FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers